These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 9744700)

  • 1. Octreotide in the treatment of intestinal lymphangiectasia.
    Ballinger AB; Farthing MJ
    Eur J Gastroenterol Hepatol; 1998 Aug; 10(8):699-702. PubMed ID: 9744700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case with intestinal lymphangiectasia successfully treated with slow-release octreotide.
    Filik L; Oguz P; Koksal A; Koklu S; Sahin B
    Dig Liver Dis; 2004 Oct; 36(10):687-90. PubMed ID: 15506669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yellow nail syndrome: treatment with octreotide.
    Hillerdal G
    Clin Respir J; 2007 Dec; 1(2):120-1. PubMed ID: 20298292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary intestinal lymphangiectasia in children: is octreotide an effective and safe option in the treatment?
    Sari S; Baris Z; Dalgic B
    J Pediatr Gastroenterol Nutr; 2010 Oct; 51(4):454-7. PubMed ID: 20512058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Octreotide management of intestinal lymphangiectasia in a teenage heart transplant patient.
    Altit G; Patel H; Morinville VD
    J Pediatr Gastroenterol Nutr; 2012 Jun; 54(6):824-7. PubMed ID: 21768882
    [No Abstract]   [Full Text] [Related]  

  • 6. Primary intestinal and thoracic lymphangiectasia: a response to antiplasmin therapy.
    MacLean JE; Cohen E; Weinstein M
    Pediatrics; 2002 Jun; 109(6):1177-80. PubMed ID: 12042562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to treat an extensive form of primary intestinal lymphangiectasia?
    Troskot R; Jurčić D; Bilić A; Gomerčić Palčić M; Težak S; Brajković I
    World J Gastroenterol; 2015 Jun; 21(23):7320-5. PubMed ID: 26109821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Octreotide in intestinal lymphangiectasia: lack of a clinical response and failure to alter lymphatic function in a guinea pig model.
    Makhija S; von der Weid PY; Meddings J; Urbanski SJ; Beck PL
    Can J Gastroenterol; 2004 Nov; 18(11):681-5. PubMed ID: 15565209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of the yellow nail syndrome associated with massive chylous ascites, pleural and pericardial effusions.
    Malek NP; Ocran K; Tietge UJ; Maschek H; Gratz KF; Trautwein C; Wagner S; Manns MP
    Z Gastroenterol; 1996 Nov; 34(11):763-6. PubMed ID: 8956479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Yellow nail syndrome associated with intestinal lymphangiectasia].
    Desramé J; Béchade D; Patte JH; Jean R; Karsenti D; Coutant G; Algayres JP; Daly JP
    Gastroenterol Clin Biol; 2000; 24(8-9):837-40. PubMed ID: 11011259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary intestinal lymphangiectasia successfully treated with octreotide.
    Kuroiwa G; Takayama T; Sato Y; Takahashi Y; Fujita T; Nobuoka A; Kukitsu T; Kato J; Sakamaki S; Niitsu Y
    J Gastroenterol; 2001 Feb; 36(2):129-32. PubMed ID: 11227670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Primary intestinal lymphangiectasia: effectiveness of treatment with slow-release octreotide].
    Balboa A; Perelló A; Mearin F
    Med Clin (Barc); 2004 Sep; 123(8):319. PubMed ID: 15373983
    [No Abstract]   [Full Text] [Related]  

  • 13. Spontaneous neonatal chylothorax treated with octreotide.
    Siu SL; Lam DS
    J Paediatr Child Health; 2006; 42(1-2):65-7. PubMed ID: 16487393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What are the objectives of treatment for intestinal lymphangiectasia?
    Takahashi H; Imai K
    J Gastroenterol; 2001 Feb; 36(2):137-8. PubMed ID: 11227672
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful treatment of protein-losing enteropathy induced by intestinal lymphangiectasia in a liver cirrhosis patient with octreotide: a case report.
    Lee HL; Han DS; Kim JB; Jeon YC; Sohn JH; Hahm JS
    J Korean Med Sci; 2004 Jun; 19(3):466-9. PubMed ID: 15201518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Octreotide in the treatment of congenital chylothorax.
    Rasiah SV; Oei J; Lui K
    J Paediatr Child Health; 2004; 40(9-10):585-8. PubMed ID: 15367160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Octreotide in Hennekam syndrome-associated intestinal lymphangiectasia.
    Al Sinani S; Rawahi YA; Abdoon H
    World J Gastroenterol; 2012 Nov; 18(43):6333-7. PubMed ID: 23180957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients.
    Nikou GC; Toumpanakis C; Katsiari C; Charalambopoulos D; Sfikakis PP
    J Clin Rheumatol; 2007 Jun; 13(3):119-23. PubMed ID: 17551375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful resection of localized intestinal lymphangiectasia post-Fontan: role of (99m)technetium-dextran scintigraphy.
    Connor FL; Angelides S; Gibson M; Larden DW; Roman MR; Jones O; Currie BG; Day AS; Bohane TD
    Pediatrics; 2003 Sep; 112(3 Pt 1):e242-7. PubMed ID: 12949320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can octreotide be the first line treatment for chylothorax?
    Leelahanon S; Petlek W; Sontimuang W; Pochanart P; Tepakorn V; Ruangpeg S
    J Med Assoc Thai; 2003 Aug; 86 Suppl 3():S741-5. PubMed ID: 14700175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.